Abstract
Background: Data on the safety and efficacy of SARS-CoV-2 vaccines in immunocompromised populations are sparse.
Methods: We conducted a prospective study of 77 heart transplant (HT) recipients vaccinated with two doses of BNT162b2 vaccine and monitored for adverse events following both doses, the receptor-binding domain (RBD) IgG response, and neutralizing antibodies.
Results: BNT162b2 vaccination was associated with a low rate of adverse events, characterized mostly by pain at the injection site. By a mean 41 days post second dose there were no clinical episodes of rejection, as suggested by a troponin leak or allograft dysfunction. At a mean 21 days following the second dose, IgG anti-RBD antibodies were detectable in 14 (18%) HT recipients. Immune sera neutralized SARS-CoV-2 pseudo-virus in 8 (57%) of those with IgG anti-RBD antibodies. Immunosuppressive regimen containing mycophenolic acid was associated with lower odds of an antibody response (OR = 0.12, p = 0.042).
Conclusions: Whether a longer time-frame for observation of an antibody response is required after vaccination in immunosuppressed individuals remains unknown.
Keywords: BNT162b2 vaccine; antibody response; heart transplantation.
【저자키워드】 BNT162b2 vaccine, Antibody Response, heart transplantation., 【초록키워드】 SARS-CoV-2, IgG, Efficacy, Vaccine, BNT162b2 vaccine, vaccination, Neutralizing antibodies, antibody, Antibody Response, Prospective Study, troponin, SARS-CoV-2 vaccines, SARS-CoV-2 vaccine, Population, BNT162b2, adverse events, Receptor-binding domain, RBD, sera, adverse event, Pain, Immunocompromised, Heart transplantation, allograft dysfunction, dose, Immunosuppressed, Anti-RBD antibody, regimen, mycophenolic acid, IgG response, observation, dysfunction, recipients, second dose, individual, injection, Anti-RBD antibodies, injection site, doses, recipient, rejection, pseudo-virus, neutralized, detectable, required, conducted, characterized, suggested, the receptor-binding domain, of BNT162b2, 【제목키워드】 vaccination, clinical,